Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05727800 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, First-in-human Study of VX-668
A Phase 1 study of Alpha-1 Antitrypsin Deficiency, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
- 5
- Study locations
NCT05727800 is a Phase 1 study of Alpha-1 Antitrypsin Deficiency that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 114 participants, below the 3,072-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05727800, a Phase 1 study of Alpha-1 Antitrypsin Deficiency, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-668
Study Locations (5)
Florida
- University of Florida - Gainesville
- Central Florida Pulmonary Group, P.A. - Orlando
Arizona
- Celerion - Tempe - Tempe
Kansas
- ICON Lenexa - Lenexa
Utah
- ICON Salt Lake City - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2024-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05727800
The ClinicalTrials.gov registry entry for NCT05727800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,072-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (96% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05727800 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Florida, Arizona, Kansas.
Frequently Asked Questions
What is clinical trial NCT05727800 about?
NCT05727800 is a clinical study titled "A Phase 1, First-in-human Study of VX-668". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.
What is the current status of trial NCT05727800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2023-02-08. Estimated completion is 2024-02-13.
What conditions does trial NCT05727800 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
What interventions are being tested in trial NCT05727800?
The interventions under investigation include: Placebo (DRUG), VX-668 (DRUG).
Who is sponsoring clinical trial NCT05727800?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05727800 being conducted?
This trial has 5 study locations across Arizona, Florida, Kansas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
RECRUITING · Phase 1
-
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
RECRUITING · Phase 1
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.